| Motexafin lutetium | |
|---|---|
 |
|
| Other names | Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123 |
| Identifiers | |
| CAS number | 246252-04-0 |
| PubChem | 3081907 |
| SMILES |
CC([O-])=O.CCC1=C2[N-]C(/C=C3N=C(/C=N/C4=CC(OCCOCCOCCOC)=C(OCCOCCOCCOC)C=C4/N=C/C(C(C)=C/5CCCO)=[N]([Lu+3])C5=C/2)C(C)=C\3CCCO)=C1CC
|
| Properties | |
| Molecular formula | C52H72LuN5O14 |
| Molar mass | 1166.12 g mol−1 |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) | |
| Infobox references | |
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It has also been tested for use in photoangioplasty (photodynamic treatment of diseased arteries).[1]
Phase II clinical trials were in progress in 1999.[2]
A phase I trial for prostate cancer reported in 2009.[3]
|
|
Wikis
Search